| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
14.73(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$129.52 - $225.13 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 664 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
50,000 |
100,397 |
1,205,681 |
5,584,204 |
| Total Sell Value |
$7,475,024 |
$15,909,372 |
$215,448,356 |
$1,085,316,909 |
| Total People Sold |
1 |
2 |
7 |
9 |
| Total Sell Transactions |
3 |
6 |
13 |
52 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Glazer Donald W. |
Director |
– • – |
2016-09-22 |
4 |
AS |
$31.13 |
$778,561 |
I/I |
(25,010) |
100,045 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2016-09-21 |
4 |
AS |
$31.19 |
$508,958 |
I/I |
(16,318) |
125,055 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2016-09-20 |
4 |
AS |
$31.01 |
$255,615 |
I/I |
(8,243) |
141,373 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2016-09-19 |
4 |
AS |
$31.56 |
$1,348,487 |
I/I |
(42,691) |
149,616 |
|
- |
|
| Huang Jane |
CMO, Hematology |
• – – |
2016-09-02 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
300,000 |
|
- |
|
| Peterson Amy C. |
CMO, Immuno-oncology |
• – – |
2016-08-22 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
300,000 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2016-07-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
3 |
4,881,997 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2016-07-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
250,000 |
4,882,000 |
|
- |
|
| Li Ji |
EVP and Gl. Head of Bus. Dev. |
• – – |
2016-05-03 |
4 |
A |
$0.00 |
$0 |
D/D |
475,000 |
475,000 |
|
- |
|
| Merck Sharp & Dohme Research Gmbh |
10% Owner |
– – • |
2016-02-08 |
4 |
A |
$0.00 |
$0 |
I/I |
7,942,314 |
7,942,314 |
|
- |
|
| Merck Sharp & Dohme Research Gmbh |
10% Owner |
– – • |
2016-02-08 |
4 |
A |
$0.00 |
$0 |
I/I |
23,646,724 |
5,128,205 |
|
- |
|
| Hillhouse Capital Management, Ltd. |
10% Owner |
– – • |
2016-02-08 |
4 |
B |
$0.00 |
$0 |
I/I |
9,100,000 |
39,726,779 |
1.42 |
- |
|
| Hillhouse Capital Management, Ltd. |
10% Owner |
– – • |
2016-02-08 |
4 |
A |
$0.00 |
$0 |
I/I |
30,626,779 |
30,626,779 |
|
- |
|
| 14159, L.p. |
Director |
– • • |
2016-02-08 |
4 |
B |
$24.00 |
$45,904,320 |
I/I |
1,912,680 |
1,723,306 |
2.25 |
- |
|
| 14159, L.p. |
Director |
– • • |
2016-02-08 |
4 |
OE |
$0.68 |
$1,750,000 |
I/I |
2,592,593 |
639,600 |
|
- |
|
| 14159, L.p. |
Director |
– • • |
2016-02-08 |
4 |
A |
$0.00 |
$0 |
I/I |
77,742,164 |
70,865,132 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2016-02-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
214,531 |
|
- |
|
| Wang Xiaodong |
Director |
– • – |
2016-02-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
16,344,143 |
|
- |
|
| Oyler John |
CEO |
• • • |
2016-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
9,398,380 |
59,780,349 |
|
- |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2016-02-08 |
4 |
B |
$1.85 |
$120,250 |
D/D |
65,000 |
65,000 |
2.74 |
- |
|
| Citic Pe Funds Ltd |
10% Owner |
– – • |
2016-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
19,601,138 |
19,601,138 |
|
- |
|
| Yuan Ruirong |
Chief Medical Officer |
• – – |
2016-02-08 |
4 |
B |
$1.85 |
$240,500 |
D/D |
130,000 |
130,000 |
2.74 |
- |
|
| Oyler John |
Chief Executive OfficeOfficer |
• • • |
2016-02-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
18,102,188 |
|
- |
|
| Oyler John |
Chief Executive OfficeOfficer |
• • • |
2016-02-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
50,381,969 |
|
- |
|
| Glazer Donald W. |
Director |
– • – |
2016-02-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,500,000 |
|
- |
|
527 Records found
|
|
Page 21 of 22 |
|
|
3.80 (2.28%) 
